EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study

Maxim John Levy Barnett iD, Justin Lam, Mikaela Nikkola Jara-Tantoco, Carlo Casipit, Sarah Eidbo, Catherine Anastasopoulou

Endocrine Connections · 01.07.2025 · 14 (7)

DOI: 10.1530/ec-25-0293 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Endocrine Connections, online erschienen am 18.07.2025. Verfasst von Maxim John Levy Barnett und 5 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Teprotumumab, a monoclonal antibody that antagonizes the insulin-like growth factor 1 receptor, is the first medication within the United States to receive Food and Drug Administration (FDA) approval for thyroid eye disease (TED). The FDA recently issued a warning regarding otologic complications, such as hearing loss. We aimed to study the association between teprotumumab and sensorineural hearing loss in thyrotoxic patients with TED. A real-world retrospective cohort study was performed through the TriNetX Collaborative Network (globally de-identified database) over a 5-year period. Inclusion criteria were patients at least 18 years of age with a diagnosis of Graves’ disease and TED, and were stratified into two cohorts: those treated with teprotumumab and those who were not. Propensity score-matching was performed for an even balance among cohorts (adjusting for age, sex, race, ethnicity, comorbidities, medications, smoking, and laboratory values), providing 532 patients per cohort. We identified a significantly higher risk difference of sensorineural hearing loss in patients treated with teprotumumab compared to those without exposure (risk difference 8.415%, 95% CI 4.954–11.876; 12.222 versus 3.808%), with a near three-fold increased relative risk for acquiring sensorineural hearing loss (risk ratio 3.21, 95% CI 1.936–5.323, P < 0.0001) over a 5-year period. Although the mechanism of teprotumumab-induced hearing loss remains unknown, and there is a lack of data to identify patients at risk (or those more likely to recover), our study confirms a higher risk for sensorineural hearing loss, which patients and providers alike must be aware of. Further studies providing prospective data are required to confirm such findings.

Schlagwörter

Stichwörter der Autor:innen

Graves’ ophthalmopathysensorineural hearing lossteprotumumabthyroid eye disease

Autor:innen und Institutionen

ORCID-Profile: Maxim John Levy Barnett

Zitieren

APA

Barnett, M. J. L., Lam, J., Jara-Tantoco, M. N., Casipit, C., Eidbo, S., & Anastasopoulou, C. (2025). Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study. Endocrine Connections, 14(7). https://doi.org/10.1530/ec-25-0293

Vancouver

Barnett MJL, Lam J, Jara-Tantoco MN, Casipit C, Eidbo S, Anastasopoulou C. Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study. Endocrine Connections. 2025;14(7). doi:10.1530/ec-25-0293

BibTeX
@article{Barnett2025,
  author = {Barnett, Maxim John Levy and Lam, Justin and Jara-Tantoco, Mikaela Nikkola and Casipit, Carlo and Eidbo, Sarah and Anastasopoulou, Catherine},
  title = {Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study},
  journal = {Endocrine Connections},
  year = {2025},
  volume = {14},
  number = {7},
  doi = {10.1530/ec-25-0293}
}
Kostenlos starten →